Cargando…

Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers

INTRODUCTION: We examined the influence of common preanalytical factors on the measurement of Alzheimer's disease–specific biomarkers in human plasma. METHODS: Amyloid β peptides (Aβ[1-40], Aβ[1-42]) and total Tau plasma concentrations were quantified using fully automated Roche Elecsys assays....

Descripción completa

Detalles Bibliográficos
Autores principales:	Rózga, Małgorzata, Bittner, Tobias, Batrla, Richard, Karl, Johann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Special Section: Blood-Based Biomarkers for Alzheimer's Disease & Related Dementias. (Editor: Henrik Zetterberg)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446057/ https://www.ncbi.nlm.nih.gov/pubmed/30984815 http://dx.doi.org/10.1016/j.dadm.2019.02.002

Ejemplares similares

Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology
por: Barupal, Dinesh Kumar, et al.
Publicado: (2019)

Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease
por: Eruysal, Emily, et al.
Publicado: (2019)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Blood-based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider
por: Zetterberg, Henrik, et al.
Publicado: (2019)

Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer's disease dementia
por: Winston, Charisse N., et al.
Publicado: (2019)

Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease
por: Nabers, Andreas, et al.
Publicado: (2019)

Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment
por: Liu, Shan, et al.
Publicado: (2019)

A proteomic signature for dementia with Lewy bodies
por: O'Bryant, Sid E., et al.
Publicado: (2019)

Posttraumatic stress disorder and total amyloid burden and amyloid-β 42/40 ratios in plasma: Results from a pilot study of World Trade Center responders
por: Clouston, Sean A.P., et al.
Publicado: (2019)

Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study
por: O'Bryant, Sid E., et al.
Publicado: (2019)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition
por: Osborn, Katie E., et al.
Publicado: (2019)

Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times
por: Mattke, Soeren, et al.
Publicado: (2020)

The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021)

Apolipoproteins and Alzheimer's pathophysiology
por: Koch, Manja, et al.
Publicado: (2018)

Molecular markers of neuropsychological functioning and Alzheimer's disease
por: Edwards, Melissa, et al.
Publicado: (2015)

A blood screening test for Alzheimer's disease
por: O'Bryant, Sid E., et al.
Publicado: (2016)

Blood-based metabolic signatures in Alzheimer's disease
por: de Leeuw, Francisca A., et al.
Publicado: (2017)

MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
por: Guedes, Joana R., et al.
Publicado: (2015)

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke
por: Weinstein, Galit, et al.
Publicado: (2016)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

Deep learning shows no morphological abnormalities in neutrophils in Alzheimer's disease
por: Chabrun, Floris, et al.
Publicado: (2021)

Plasma microRNA vary in association with the progression of Alzheimer's disease
por: Guévremont, Diane, et al.
Publicado: (2022)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

Alterations of membrane protein expression in red blood cells of Alzheimer's disease patients
por: Várady, György, et al.
Publicado: (2015)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
por: Keshavan, Ashvini, et al.
Publicado: (2018)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes
por: Bettcher, Brianne M., et al.
Publicado: (2016)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d94b2h2r59qiun24p587i8j8ik